Profund Advisors LLC Makes New Investment in KalVista Pharmaceuticals, Inc. $KALV

Profund Advisors LLC bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 10,020 shares of the specialty pharmaceutical company’s stock, valued at approximately $113,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Emerald Mutual Fund Advisers Trust increased its position in KalVista Pharmaceuticals by 26.4% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after buying an additional 160,759 shares in the last quarter. Emerald Advisers LLC increased its holdings in shares of KalVista Pharmaceuticals by 15.6% during the second quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock valued at $11,735,000 after acquiring an additional 139,859 shares in the last quarter. Whalen Wealth Management Inc. bought a new position in shares of KalVista Pharmaceuticals during the second quarter valued at $124,000. Goldman Sachs Group Inc. raised its position in shares of KalVista Pharmaceuticals by 3.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after purchasing an additional 12,263 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in KalVista Pharmaceuticals by 3.4% in the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock worth $611,000 after purchasing an additional 1,762 shares in the last quarter.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 3,328 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.55, for a total value of $38,438.40. Following the transaction, the chief executive officer owned 398,981 shares in the company, valued at $4,608,230.55. This represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,336 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the completion of the transaction, the insider directly owned 122,505 shares in the company, valued at approximately $1,644,017.10. The trade was a 1.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,184 shares of company stock valued at $413,348 in the last ninety days. Insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $13.62 on Monday. The stock has a market capitalization of $688.44 million, a price-to-earnings ratio of -3.46 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $17.28. The business’s fifty day moving average price is $12.17 and its 200-day moving average price is $12.81.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million. Equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Analyst Ratings Changes

KALV has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research report on Friday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Citizens Jmp cut their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Tuesday, November 11th. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.63.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).